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CORRESPONDENCE
Letters to the Editor
The CAPRIE-Like Subgroups of
CHARISMA: A CAPRIEciously
Biased Analysis of an
unCHARISMAtic Truth
In a textbook example of an improper subgroup analysis (1) (one
defined by events subsequent to randomization, in this case
fabricating new “CAPRIE [Clopidogrel Versus Aspirin in Patients
at Risk of Ischemic Events]-like” inclusion criteria), Bhatt et al. (2)
present data suggesting that persons with a prior history of stroke,
myocardial infarction (MI), or peripheral vascular disease (PVD)
may benefit from long-term dual antiplatelet therapy with aspirin
plus clopidogrel versus aspirin alone. It is illuminating to examine
this analysis in the historical and statistical context of the clinical
trial evidence from which it was derived.
In the CAPRIE trial (3), a trial twice as large as this “CAPRIE-
like” CHARISMA (Clopidogrel for High Atherothrombotic Risk,
Ischemic Stabilization, Management, and Avoidance) subgroup, a
marginally statistically significant result (p  0.043) was observed
for the primary end point, with statistical heterogeneity of treat-
ment effect (p  0.042) being observed between the 3 predefined
subgroups of patients with recent stroke, MI, or PVD. Only the
PVD subgroup benefited from the use of clopidogrel versus
aspirin. Despite statistically stronger evidence of heterogeneity of
(p  0.042) than of overall treatment effect (p  0.043), the
CAPRIE trial’s authors concluded that their hypothesis of univer-
sal superiority of clopidogrel over aspirin for all vascular disease
was correct anyway and presented in their primary manuscript
another improper post hoc subgroup analysis designed to make
their data comply with their hypothesis. Specifically, they analyzed
patients with newly fabricated inclusion criteria of any prior history
of coronary artery disease and, unlike the actual CAPRIE trial MI
patient subgroup, showed a statistically significant reduction in
recurrent vascular events.
History has now repeated itself. The most statistically signifi-
cant results presented in the primary CHARISMA trial report (4)
were excessive “moderate” bleeding events in the dual-therapy
group (p  0.001) and excess cardiovascular mortality in the
predefined primary prevention subcohort (p  0.01) treated with
dual therapy. The primary end point was negative. Ironically, and
perhaps predictably, 10 years after the CAPRIE trial, the
CHARISMA trial’s authors have suddenly selectively embraced
the value of heterogeneity of treatment effect (between the primary
and secondary prevention subcohorts) statistically evident in the
CHARISMA trial (p  0.045), using it as a philosophical
springboard to manipulate the data of the CHARISMA trial to fit
their hypothesis of the universal superiority of clopidogrel (this
time when combined with aspirin) over aspirin via the currently
published analysis.
Positive subgroups within negative trials such as the
CHARISMA trial are virtually always the result of confounding or
bias, especially post hoc defined subgroups. How many additional
unpublished subgroup analyses of the CHARISMA trial have
been performed? Are we to ignore the results of the MATCH
(Management of Atherothrombosis With Clopidogrel in High-
Risk Patients) trial (5), which showed statistically significant net
harm for patients with recent stroke/transient ischemic attack
(TIA) treated with clopidogrel plus aspirin versus clopidogrel
alone, in favor of those of an improper post hoc subgroup analysis
with less than one-half of the analogous patient population? No
clinical trial has ever shown superiority of clopidogrel, plus or
minus aspirin, over aspirin or clopidogrel alone for preventing
recurrent vascular events in patients with recent or remote history
of stroke/TIA.
If a randomized trial of aspirin plus clopidogrel versus aspirin
alone in a population of patients with any prior history of stroke,
MI, and/or PVD is performed, I predict it will show no statistically
significant net benefit.
*James M. Gebel, Jr., MD, MSc, FAHA
*Medical Director
Jewish Hospital Comprehensive Stroke Center
6400 Dutchmans Lane, Suite 145
Louisville, Kentucky 40205
E-mail: j.gebel@att.net
doi:10.1016/j.jacc.2007.06.049
REFERENCES
1. Freemantle N. Interpreting the results of secondary end points and
subgroup analyses in clinical trials: should we lock the crazy aunt in the
attic? BMJ 2001;322:989–91.
2. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial
infarction, stroke, or symptomatic peripheral arterial disease in the
CHARISMA trial. J Am Coll Cardiol 2007;49:1982–8.
3. CAPRIE Steering Committee. A randomised, blinded, trial of clopi-
dogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet 1996;348:1329–39.
4. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus
aspirin alone for the prevention of atherothrombotic events. N Engl
J Med 2006;354:1706–17.
5. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel
compared with clopidogrel alone after recent ischaemic stroke or
transient ischaemic attack in high-risk patients (MATCH): random-
ised, double-blind, placebo-controlled trial. Lancet 2004;364:331–7.
Reply
Dr. Gebel takes issue with our recent subgroup analysis of the
CHARISMA (Clopidogrel for High Atherothrombotic Risk,
Ischemic Stabilization, Management, and Avoidance) study,
which he labels improper because he incorrectly believes it was
defined by events that occurred after randomization (1,2). In fact,
the subgroup consisted of patients with documented ischemic
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events before randomization and was based upon a liberalized
version of the inclusion criteria of the CAPRIE (Clopidogrel
Versus Aspirin in Patients at Risk of Ischemic Events) trial (3). Of
course, any subgroup needs to be interpreted with caution before
the results are applied broadly and we went to great lengths in the
paper to interpret our findings very conservatively and with the
appropriate caveats. The subgroup as defined is one that represents
a population in which it is biologically plausible that there might
be benefit, and the findings are in keeping with and an extension
of several other clopidogrel trials, such as the CLARITY (Clopi-
dogrel as Adjunctive Reperfusion Therapy), COMMIT (Ran-
domized Placebo-Controlled Trial of Adding Clopidogrel to
Aspirin in 46,000 Acute Myocardial Infarction Patients), and
CURE (Clopidogrel in Unstable Angina to Prevent Recurrent
Events) studies (4–6). Importantly, we conclude by stating that
further study is necessary to validate our findings.
Dr. Gebel’s comparisons of our results to the CAPRIE trial, as
well as to the MATCH (Management of Atherothrombosis With
Clopidogrel in High-Risk Patients) trial, are flawed (7). In the
CHARISMA study, the comparison was clopidogrel to placebo,
with a background of aspirin therapy. In the CAPRIE trial, the
comparison was clopidogrel versus an active control, aspirin, with
no placebo arm. The MATCH trial was essentially a comparison
of aspirin versus placebo, with a background of clopidogrel. Thus,
interpretation of these trials and cross-comparison is not as simple
as Dr. Gebel portrays.
He concludes by stating that he does not think the findings
would be replicated if the trial were repeated. Indeed, one trial has
already been announced that will test the hypothesis of whether
adding a novel antithrombotic to aspirin is superior to aspirin alone
in patients with prior myocardial infarction, stroke, or peripheral
arterial disease. Likely, other trials will also test the value of
additional antithrombotic therapy in this patient population, such
that we will ultimately have further data to guide decision making
about optimal antithrombotic strategies for patients with prior
ischemic events.
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A Perspective on
Coronary Revascularization
in the PROactive 05 Study
Erdmann et al. (1) should be applauded for their recent contribu-
tion entitled “The Effect of Pioglitazone on Recurrent Myocardial
Infarction in 2,445 Patients With Type 2 Diabetes and Previous
Myocardial Infarction”. The PROactive 05 study is a post hoc
exploratory analysis of patients enrolled in the main PROactive
study that entered the study with a previous myocardial infarc-
tion (MI) (2). The investigators conclude that in high-risk
patients with type 2 diabetes and previous MI, pioglitazone
significantly reduced the occurrence of fatal and nonfatal MI
and acute coronary syndrome (1). These results provide criti-
cally important clinical data for pioglitazone, in light of Nissen
and Wolski’s (3) recent analysis suggesting increased risk of MI
with rosiglitazone use.
In the PROactive 05 study, cardiac intervention is defined as
coronary artery bypass graft (CABG) or percutaneous coronary
intervention (PCI) (1). Approximately 40% of the patients at
baseline had a previous PCI/CABG (1). In Table 5 under the
heading for individual end points, the investigators reported that
coronary revascularization (CABG and PCI) demonstrated a
nonsignificant absolute risk reduction (ARR) of 2% (1). This is
the most dynamic ARR among any of the individual end points.
This finding may be supported by the results of a recent
meta-analysis. That meta-analysis evaluated the effect of thia-
zolidinediones (TZDs) on reducing the risk of repeat target
vessel revascularization (TVR) after PCI (4). The results
suggested that TZDs, in fact, significantly reduce repeat TVR
after PCI (4). Although relative risk is reduced regardless of the
TZD used or the presence of diabetes, patients with diabetes
and studies evaluating pioglitazone seemed to show the most
robust benefit (4).
Because a large portion of patients at baseline had undergone
a previous coronary intervention, it would be interesting to
evaluate these patients separately to determine if this subgroup
would demonstrate a significant reduction in any coronary
revascularization. Additionally, it may be compelling to evaluate
pioglitazone’s effect on CABG and PCI separately. We suspect
that the majority of the absolute risk reduction for this end point
is driven by the PCI subset of patients. Such a finding could
substantiate the results reported in the meta-analysis by Riche et al.
(4) and may cast a new light on the darkening link between TZDs
and MI.
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